GE HealthCare management to present at upcoming investor conference

CHICAGO–(BUSINESS WIRE)–GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at Citi’s 2025 Medtech and Life Sciences Access Day on February 27, 2025 at 2:15pm CT / 3:15 pm ET.

A webcast of this event can be accessed at the GE HealthCare website: https://investor.gehealthcare.com/news-events/events on the date and time listed above.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

Contacts

GE HealthCare Investor Contact:
Carolynne Borders

(631) 662-4317

carolynne.borders@gehealthcare.com

GE HealthCare Media Contact:
Jennifer Fox

(414) 530-3027

jennifer.r.fox@gehealthcare.com

Staff

Recent Posts

AMEEREX Signs MOU to Acquire 45.6 million-Ounce Silver-Gold Project in Nevada, Expanding Its North American Precious-Metals Portfolio

ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…

16 minutes ago

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…

6 hours ago